What is Geldanamycin?

Geldanamycin is an antibiotic that is quite toxic to human beings. This drug seems to be beneficial in preventing the growth of some infectious organisms and can play a useful role in the treatment of other health conditions. Scientists in cancer treatment think that the specific effects of the drug in the body can help treat the growth of tumor. Due to the internal toxicity of geldanamycin, synthetic copies with several improvements have been created for research purposes.

first discovered in 1970, Geldanamycin is a natural product of a bacterial species called Streptococcus hygroscosicapions . Through scientific studies, scientists have found that the substance could have a beneficial effect on the replication of the virus. Herpes Simplex is one of such infectious organisms that Geldanamycin has antibiotic activity against.

Research has also found out how the substance acts inside the body, which made the substance an attractive medicine other conditions. Acts directly on the molecule called the protein of the thermalShock 90 (HSP90) to block it in their normal work. This protein is very common in the body and acts as a guard for many other molecules. Some of these other molecules are involved in cell growth and replication, a process that is an integral part of tumor cells and viral infections such as Herpes Simplex.

This protein therefore reduces the replication of the virus, because the viruses must bear the host cell machine to help the viral particle. Compared to antibiotics used to combat bacteria or mushrooms, there are few antibiotics that target viruses. It may also potentially prevent cancer cell replication because the replication molecule that controls replication does not help HSP-90. The main problem with Geldanamycin itself for medical researchers is that it is very toxic to humans and can be seen by the liver. Nero alsoIt deserts in water that represents complications for the production of injections and other liquid medicines.

Instead of concentrating on Geldanamycin itself, scientists decided to create a synthetic copies of a molecule with minor improvements into the structure. These small improvements are differences in the part of the molecule known as 17-Substituent and usually have synthetic analogs that relate to the type of improvement present in this 17-Substituent, such as 17-yoylamino-twothoxygeldamycin (17-AAG). Since 2011, research has been carried out in the effectiveness of these drugs against tumors or viral infections.